Why the study?
Increased cancer survival has led to rising cardiovascular complications from anticancer therapies, creating a need for dedicated cardio-oncology services to manage and prevent cardiotoxicity.
Proposes a spoke-hub model for cardio-oncology services in Italy to address the growing need for specialized cardiovascular care in cancer patients.
Answers are grounded in this paper and cite their sources.
Supports expert cardio-oncology input for therapy-related cardiotoxicity; leaves open optimal care models and training standards.
In the last 20 years, a substantial improvement in the efficacy of cancer treatment has induced a progressive increase in cancer survival, with an obvious parallel increase in morbidity and mortality related to the adverse effects of anticancer therapy, in particular, cardiovascular complications. In relation to the peculiar aspects related to cardiac and vascular toxicity, clinical management of patients should be ideally reserved for experts in the field of this novel medical discipline, which has been defined as cardio-oncology. The rationale for this choice corresponds to the aim of identifying patients more prone to developing cardiovascular damage, prevent overt cardiotoxicity and conduct active surveillance of treated patients for early identification of cardiac and vascular involvement during short- and long-term follow-up. Due to the burden of treated cancer patients, the development of dedicated cardio-oncology services has become one of the main goals of contemporary medicine, needed to accomplish the peculiar mission of guiding the patients through the narrow path of cancer survival without the expense of cardiovascular damage. The main purpose of cardio-oncology services is to provide dedicated cardiologic care to cancer patients affected by concomitant (subclinical or overt) cardiovascular diseases, either preexisting the cancer onset or acquired during and after the time course of anticancer therapy. In this article, we describe a possible spoke-hub model of cardio-oncology services, which could be appropriately applied in Italy. Rationale, organization, definition of referral criteria, strategies, interventional programs, long-term surveillance and home assistance of this model are described and discussed.
No takes yet. Share an insight, caveat, or question.
Galderisi et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: